A. Rojas

发表

A 26-Gene Hypoxia Signature Predicts Benefit from Hypoxia-Modifying Therapy in Laryngeal Cancer but Not Bladder Cancer

Crispin J. Miller, A. Harris, P. Span, 2013, Clinical Cancer Research.

Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma.

P. Hoskin, S. Bentzen, A. Rojas, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combined radioimmunotherapy and radiotherapy of human colon carcinoma grafted in nude mice.

R. Mirimanoff, P. Coucke, J. Denekamp, 1995, Cancer research.

High-dose-rate brachytherapy with two or three fractions as monotherapy in the treatment of locally advanced prostate cancer.

P. Hoskin, G. Lowe, R. Alonzi, 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Carbogen and nicotinamide in locally advanced bladder cancer: early results of a phase-III randomized trial.

P. Hoskin, S. Bentzen, A. Rojas, 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Nicotinamide as a repair inhibitor in vivo: studies using single and fractionated X-ray doses in mouse skin and kidneys.

J. Denekamp, M. Stratford, P. Nilsson, 1996, Radiation research.

Should carbogen and nicotinamide be given throughout the full course of fractionated radiotherapy regimens?

A. Rojas, H. Johns, P. Fiat, 1993, International journal of radiation oncology, biology, physics.

Extrapolations from laboratory and preclinical studies for the use of carbogen and nicotinamide in radiotherapy.

J. Denekamp, M. Joiner, A. Rojas, 1992, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Recovery kinetics in mouse skin and CaNT tumours.

M. Joiner, A. Rojas, H. Johns, 1989, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

A therapeutic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated X-ray treatments.

J. Collier, M. Joiner, A. Rojas, 1991, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Pharmacokinetics of nicotinamide and its effect on blood pressure, pulse and body temperature in normal human volunteers.

S. Dische, M. Stratford, M. Joiner, 1992, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Contribution of lethal mutations to excision assays for tumour cell survival.

A. Rojas, R. Hodgkiss, A. Chatterjee, 1995, Acta oncologica.

ARCON: accelerated radiotherapy with carbogen and nicotinamide.

A. Rojas, 1992, BJR supplement.

Accelerated radiotherapy, carbogen, and nicotinamide (ARCON) in the treatment of advanced bladder cancer: mature results of a Phase II nonrandomized study.

P. Hoskin, A. Rojas, M. Saunders, 2009, International journal of radiation oncology, biology, physics.

Pre-treatment haemoglobin and peripheral blood lymphocyte count as independent predictors of outcome in carcinoma of cervix.

P. Hoskin, A. Rojas, I. Chong, 2014, Clinical oncology (Royal College of Radiologists (Great Britain)).

Carbogen breathing: a system for use in man.

S. Dische, B. Michael, A. Hong, 1992, The British journal of radiology.

Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial

A. Harris, H. Denley, P. Hoskin, 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Radioprotection of mouse skin by WR-2721: the critical influence of oxygen tension.

F. Stewart, J. Denekamp, B. Michael, 1982, International journal of radiation oncology, biology, physics.

The influence of prostate volume on outcome after high-dose-rate brachytherapy alone for localized prostate cancer.

P. Hoskin, H. Le, G. Lowe, 2013, International journal of radiation oncology, biology, physics.

Clinical Investigation : Genitourinary Cancer The Influence of Prostate Volume on Outcome After High-Dose-Rate Brachytherapy Alone for Localized Prostate Cancer

P. Hoskin, H. Le, G. Lowe, 2022 .

Cell kinetics and radiation pathology

J. Denekamp, A. Rojas, 1989, Experientia.

Experimental radiotherapy with WR-2721 and misonidazole.

F. Stewart, J. Denekamp, A. Rojas, 1982, International journal of radiation oncology, biology, physics.

Is the outlook grey for WR-2721 as a clinical radioprotector?

F. Stewart, J. Denekamp, A. Rojas, 1983, International journal of radiation oncology, biology, physics.

Radioprotection of two mouse tumors by WR-2721 in single and fractionated treatments.

F. Stewart, J. Denekamp, A. Rojas, 1983, International journal of radiation oncology, biology, physics.

Dose-escalation with CHARTWEL (continuous hyperfractionated accelerated radiotherapy week-end less) combined with neo-adjuvant chemotherapy in the treatment of locally advanced non-small cell lung cancer.

A. Rojas, M. Saunders, E. Wilson, 2002, Clinical oncology (Royal College of Radiologists (Great Britain)).

High-dose-rate brachytherapy alone given as two or one fraction to patients for locally advanced prostate cancer: acute toxicity.

P. Hoskin, G. Lowe, R. Alonzi, 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Nicotinamide pharmacokinetics in humans: effect of gastric acid inhibition, comparison of rectal vs oral administration and the use of saliva for drug monitoring.

P. Hoskin, M. Stratford, A. Rojas, 1996, British Journal of Cancer.

Dosimetric predictors of biochemical control of prostate cancer in patients randomised to external beam radiotherapy with a boost of high dose rate brachytherapy.

P. Hoskin, G. Lowe, A. Rojas, 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Fractionation studies with WR-2721: normal tissues and tumour.

F. Stewart, J. Soranson, J. Denekamp, 1986, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

The influence of X ray dose levels on normal tissue radioprotection by WR-2721.

J. Denekamp, A. Rojas, 1984, International journal of radiation oncology, biology, physics.

An open-label trial of the prophylactic administration of voriconazole in patients who undergo allogeneic hematopoietic stem cell transplantation: study protocol

F. Stewart, J. Denekamp, A. Saito, 2018, Nagoya journal of medical science.

Effect of glutathione depletion on radiosensitivity in vivo

J. Soranson, J. Denekamp, K. Smith, 1984 .

Carbogen and nicotinamide in the treatment of bladder cancer with radical radiotherapy.

P. Hoskin, M. Stratford, A. Rojas, 1997, British Journal of Cancer.

Pharmacokinetics of varying doses of nicotinamide and tumour radiosensitisation with carbogen and nicotinamide: clinical considerations.

M. Stratford, A. Rojas, R. Hodgkiss, 1993, British Journal of Cancer.

Enhancement of tumor radiosensitivity and reduced hypoxia-dependent binding of a 2-nitroimidazole with normobaric oxygen and carbogen: a therapeutic comparison with skin and kidneys.

G. Wilson, U. Carl, M. Joiner, 1992, International journal of radiation oncology, biology, physics.

Management of cancer of the head and neck--a cocktail with your PORT?

A. Rojas, M. Saunders, 2004, The New England journal of medicine.

Modifiers of radiosensitivity

J. Denekamp, A. Rojas, 1989, Experientia.

Is sensitization with nicotinamide and carbogen dependent on nicotinamide concentration at the time of irradiation?

J. Denekamp, M. Stratford, A. Rojas, 2004, International journal of radiation biology.

Radiosensitisation in normal tissues with oxygen, carbogen or nicotinamide: therapeutic gain comparisons for fractionated x-ray schedules.

J. Fowler, B. Vojnovic, C. Martindale, 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Normobaric oxygen as a sensitizer of hypoxic tumor cells.

S. Dische, A. Hong, A. Rojas, 1989, International journal of radiation oncology, biology, physics.

Renal damage in the mouse: repair kinetics at 2 and 7 Gy per fraction.

M. Joiner, A. Rojas, H. Johns, 1993, Radiation research.

Thiol radioprotection in vivo: the critical role of tissue oxygen concentration.

F. Stewart, J. Denekamp, B. Michael, 1981, The British journal of radiology.

Radioprotection of mouse skin by WR-2721 in single and fractionated treatments.

F. Stewart, A. Rojas, 1982, The British journal of radiology.

Radioprotection in Vivo: Cellular Heterogeneity and Fractionation

J. Denekamp, A. Rojas, 1987 .

Interaction of radiosensitizers and WR-2721. I. Modification of skin radioprotection.

F. Stewart, J. Denekamp, A. Rojas, 1982, British Journal of Cancer.

A test of equal effect per fraction in the kidney of the mouse.

M. Joiner, A. Rojas, H. Johns, 1992, Radiation research.

Glutathione depletion in tissues after administration of buthionine sulphoximine.

D. Shrieve, J. Soranson, K. Smith, 1984, International journal of radiation oncology, biology, physics.

Administration of nicotinamide during chart: pharmacokinetics, dose escalation, and clinical toxicity.

P. Hoskin, M. Stratford, A. Rojas, 1995, International journal of radiation oncology, biology, physics.

Repopulation in murine skin after X-ray treatments with multiple fractions per day.

M. Joiner, A. Rojas, H. Johns, 1991, Radiation research.

Does the repair capacity of skin change with repeated exposure to X-rays?

M. Joiner, A. Rojas, H. Johns, 1989, International journal of radiation biology.

Mature results of a randomized trial of accelerated hyperfractionated versus conventional radiotherapy in head-and-neck cancer.

M. Parmar, S. Dische, A. Rojas, 2010, International journal of radiation oncology, biology, physics.

Effect of anemia on tumor radiosensitivity under normo and hyperbaric conditions.

F. Stewart, J. Soranson, J. Denekamp, 1987, International journal of radiation oncology, biology, physics.

Effects of radiomodifiers on high and low LET responses in vivo.

J. Denekamp, A. Rojas, R. Maughan, 1984, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Redox competition and radiosensitivity: implications for testing radioprotective compounds.

G. Stevens, J. Denekamp, A. Rojas, 1988, Pharmacology & therapeutics.

Effect of normobaric oxygen on tumor radiosensitivity: fractionated studies.

U. Carl, A. Rojas, K. Reghebi, 1990, International journal of radiation oncology, biology, physics.

Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: report of European Organization for Research and Treatment of Cancer trial 22933.

M. Piérart, M. van Glabbeke, R. Mirimanoff, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radiosensitization with normobaric oxygen and carbogen.

A. Rojas, 1991, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: mature 12-year results.

P. Hoskin, G. Lowe, A. Rojas, 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer.

P. Hoskin, G. Lowe, R. Alonzi, 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer.

P. Hoskin, G. Lowe, A. Rojas, 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

High-dose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrence.

P. Hoskin, G. Lowe, A. Rojas, 2012, International journal of radiation oncology, biology, physics.

A Phase II study of high-dose-rate afterloading brachytherapy as monotherapy for the treatment of localized prostate cancer.

P. Hoskin, A. Rojas, P. Ostler, 2008, International journal of radiation oncology, biology, physics.

Quality of life after radical radiotherapy for prostate cancer: longitudinal study from a randomised trial of external beam radiotherapy alone or in combination with high dose rate brachytherapy.

P. Hoskin, G. Lowe, A. Rojas, 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).

ARCON: accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas. The experience of the Co-operative group of radiotherapy of the european organization for research and treatment of cancer (EORTC).

J. Horiot, H. Hamers, M. Piérart, 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Induction of lethal mutations in experimental tumours after single and fractionated irradiations in vivo.

A. Rojas, R. Hodgkiss, A. Chatterjee, 1998, International journal of radiation biology.

IAEA randomised trial of optimal single dose radiotherapy in the treatment of painful bone metastases.

B. Jeremic, P. Hoskin, A. Rojas, 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Toxicity and outcome of a phase II trial of taxane‐based neoadjuvant chemotherapy and 3‐dimensional, conformal, accelerated radiotherapy in locally advanced nonsmall cell lung cancer

A. Rojas, J. Dickson, M. Saunders, 2006, Cancer.

CHART revisited: a conservative approach for advanced head and neck cancer.

S. Dische, A. Rojas, M. Saunders, 2008, Clinical oncology (Royal College of Radiologists (Great Britain)).

Administration of nicotinamide during a five- to seven-week course of radiotherapy: pharmacokinetics, tolerance, and compliance.

J. Kaanders, A. J. van der Kogel, M. Stratford, 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Enhancement of misonidazole radiosensitization by buthionine sulphoximine.

J. Soranson, J. Denekamp, K. Smith, 1984, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Pharmacokinetics of nicotinamide in cancer patients treated with accelerated radiotherapy: the experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer.

M. Bolla, J. Bernier, J. Denekamp, 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Carbogen and nicotinamide as radiosensitizers in a murine mammary carcinoma using conventional and accelerated radiotherapy.

V. Hirst, A. Rojas, H. Johns, 1996, International journal of radiation oncology, biology, physics.

Cancer Hypoxia-Modifying Therapy in Laryngeal Cancer but Not Bladder A 26-Gene Hypoxia Signature Predicts Benefit from

Crispin J. Miller, A. Harris, P. Span, 2013 .

Predictive Biomarkers and Personalized Medicine A 26-Gene Hypoxia Signature Predicts Bene fi t fromHypoxia-Modifying Therapy in Laryngeal Cancer but Not Bladder Cancer

Crispin J. Miller, A. Harris, P. Span, 2013 .

The influence of dose per fraction on repair kinetics.

M. Joiner, A. Rojas, 1989, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Experience with dose escalation using CHARTWEL (continuous hyperfractionated accelerated radiotherapy weekend less) in non-small-cell lung cancer.

P. Hoskin, A. Rojas, M. Saunders, 1998, British Journal of Cancer.

Acute and late morbidity in the treatment of advanced bladder carcinoma with accelerated radiotherapy, carbogen, and nicotinamide

P. Hoskin, A. Rojas, M. Saunders, 2005, Cancer.

Tumor sensitization and protection: influence of stromal injury on estimates of dose modification.

M. Williams, J. Denekamp, A. Rojas, 1984, International journal of radiation oncology, biology, physics.

Recovery kinetics of X-ray damage in mouse skin: the influence of dose per fraction.

M. Joiner, A. Rojas, H. Johns, 1991, International journal of radiation biology.

The influence of experimental design and data analysis on the determination of recovery kinetics of radiation damage between acute dose-rate treatments in vivo.

B. Michael, M. Joiner, A. Rojas, 1990, International journal of radiation biology.

OC-0051 QUALITY OF LIFE AFTER RADICAL RADIOTHERAPY FOR PROSTATE CANCER: RESULTS FROM A RANDOMISED TRIAL OF EBRT ± HDR-BT

P. Hoskin, G. Lowe, A. Rojas, 2012 .

Accelerated radiotherapy, carbogen and nicotinamide (ARCON) in locally advanced head and neck cancer: a feasibility study.

P. Hoskin, S. Dische, J. Denekamp, 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Nicotinamide pharmacokinetics in normal volunteers and patients undergoing palliative radiotherapy.

P. Hoskin, M. Stratford, A. Rojas, 1996, Acta oncologica.

ARCON: accelerated radiotherapy with carbogen and nicotinamide in non small cell lung cancer: a phase I/II study by the EORTC.

J. Horiot, H. Hamers, M. Piérart, 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Acute effects of accelerated radiotherapy in combination with carbogen breathing and nicotinamide (ARCON).

R. Henriksson, B. Zackrisson, J. Denekamp, 1994, Acta oncologica.

Influence of circadian rhythms on radiosensitivity: single and fractionated dose studies in mouse skin.

A. Rojas, B. Hirn-Stadler, 1991, International journal of radiation biology.